Evotec Announces Initiation of Phase I Clinical Trial of VR1 Antagonist under Partnership with Pfizer
News Aug 05, 2008
Evotec AG has announced that dose escalation studies for a Phase I clinical trial of a small molecule VR1 (vanilloid receptor 1) antagonist is being progressed by Pfizer Inc. under the collaboration with Evotec.
The Phase I study is a randomized, double-blind and placebo-controlled single ascending dose study in healthy volunteers to evaluate the compound’s safety, tolerability and pharmacokinetic profile after oral administration.
The VR1 receptor is one of the best characterized members of the transient receptor potential (TRP) family of ion channel proteins. Ion channels mediate and influence cell signalling and are attractive targets for drug discovery.
Antagonists of VR1, which prevent the activation of nerve cell signalling, are predicted to be useful in the treatment of pain, urinary incontinence and other diseases and disorders.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Drug Combo Prevents Stroke, Shows Promise for ClinicNews
Taking the clot-preventing drug clopidogrel along with aspirin may lower your risk of having a major stroke within the next 90 days following a TIAREAD MORE
Cannabidiol Significantly Reduces 'Drop Seizures' in Epilepsy PatientsNews
Study shows efficacy of cannabidiol in epilepsy treatment.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018